Quick Answer
Evofem Biosciences, Inc. reported Net Income of -$8.86 million for fiscal year 2024.
Evofem Biosciences, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$8.86M | -116.7% |
| 2023 | $52.98M | +169.1% |
| 2022 | -$76.70M | +62.6% |
| 2021 | -$205.19M | -44.2% |
| 2020 | -$142.31M | -77.8% |
| 2019 | -$80.03M | +36.3% |
| 2018 | -$125.71M | -19.4% |
| 2017 | -$105.31M | -708.9% |
| 2016 | -$13.02M | +69.8% |
| 2015 | -$43.16M | -298.9% |
| 2014 | -$10.82M | +27.9% |
| 2013 | -$15.02M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.57M | +33.7% | +12.1% |
| June 30, 2025 | -$1.78M | -232.1% | -286.6% |
| March 31, 2025 | $956.0K | +119.9% | +140.4% |
| September 30, 2024 | -$2.37M | -103.6% | -275.1% |
| June 30, 2024 | $1.35M | +115.8% | +128.1% |
| March 31, 2024 | -$4.81M | -104.3% | -107.3% |
| September 30, 2023 | $66.00M | -26.3% | +871.3% |
| June 30, 2023 | -$8.56M | +93.2% | -263.6% |
- Evofem Biosciences, Inc. showed a decrease of -116.7% in Net Income compared to the prior fiscal year.
- Over the 2013–2024 period, Evofem Biosciences, Inc.’s net income has grown by 41.0% (from -$15.02 million to -$8.86 million).
- The most recent figure is from Evofem Biosciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: